PostEra and LifeArc collaborate on novel open science initiative to develop new antiviral for COVID-19

SAN FRANCISCO: SAN FRANCISCO, May 19, 2021 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for drug discovery, today announced that it has received a grant of £100k from the independent medical charity LifeArc to support an international effort to rapidly develop a potential antiviral candidate for COVID-19....

Click to view original post